Radiography
Pulmonary hypertension. Chest radiograph in a patient with secondary pulmonary hypertension reveals enlarged pulmonary arteries. This patient was found to have an atrial septal defect.
Findings
Chest radiographic findings of pulmonary hypertension (see Images 2-3) include the following:
- Enlarged central pulmonary arteries that taper distally may be depicted.
- A dilated right heart due to right ventricular enlargement is seen as a decrease in the retrosternal space on the lateral image. Right atrial enlargement may be present if significant tricuspid regurgitation is present. This finding may be recognized by the widened right heart border in the frontal projection and enlargement of the right atrial appendage in the lateral projection, which is seen as increased retrosternal opacity above the expected location of the right ventricle.
- Peripheral vessel opacity-oligemic lung fields may be observed. This oligemia may be asymmetric. This is also a useful finding suggestive of chronic PE.
- An increase in the transverse diameter of the right interlobar artery is indicative of pulmonary hypertension. The upper limit of the transverse diameter of the right interlobar artery from its lateral aspect to the intermediate bronchus is 15 mm in women and 16 mm in men.
- The transverse diameter of the left interlobar artery is difficult to appreciate on the posteroanterior (PA) view. Using a lateral view, one can measure from the circular lucency of the left upper lobe bronchus to the posterior margin of the vessel; the upper limit is 18 mm.
- Evidence of right atrial dilatation and right ventricular dilatation may be noted.
- Kerley B lines may be present. These indicate the presence of pulmonary venous hypertension.
Causes of SPAH and their appearances include the following:
- Atrial septal defect is characterized by cardiomegaly, enlargement of the right atrium and ventricle, and enlargement of the central pulmonary arteries. Also present is rapid tapering, with increased vascularity in the periphery of the lung.
- Eisenmenger syndrome is characterized by peripheral oligemia, indicating the reversal of a left-to-right shunt due to increased vascular resistance. The peripheral vasculature is diminished, and the cardiac morphology is consistent with cor pulmonale.
Computed Tomography
Pulmonary hypertension. Spiral CT scan in a patient with pulmonary hypertension reveals enlarged pulmonary arteries and an absence of thrombosis.
Pulmonary hypertension. CT pulmonary angiogram in a 42-year-old man who experienced severe chest pain after a long flight. Image demonstrates clots in both the right and left main pulmonary arteries.
Findings
CTPA is useful in delineating the anatomic detail of the pulmonary vasculature. Contrast-enhanced images may show intraluminal abnormalities in the arteries and veins, which are useful for confirming etiologies such as thromboembolic disease.2,3,4
Sometimes, if the emboli are large, they may be seen in the pulmonary arteries on a routine contrast-enhanced CT scans.
CTPA, and often conventional pulmonary arteriography, is necessary for an adequate evaluation of chronic PE. The technique of CTPA includes a rapid infusion at 3-4 mL/s for a total of 80-120 mL. Careful review of the images on a workstation is the optimal method of detecting subtle emboli. Evaluation of the lung windows to detect abnormalities of perfusion (mosaic perfusion) is necessary, as occlusions of major pulmonary arterial branches may not be present in a subset of patients with chronic pulmonary thromboembolism.
High-resolution CT (HRCT) of the chest has a role in the evaluation of pulmonary hypertension in patients with suspected diffuse lung disease, eg, in patients with collagen vascular disease.
More than a decade ago, Kuriyama et al determined that a main pulmonary artery of 29 mm or larger, as shown on a CT scan, has a sensitivity of 69% and a specificity of 100% for predicting pulmonary hypertension. The widest portion of the main pulmonary artery within 3 cm of the bifurcation was used to determine the value. In addition, Tan et al demonstrated that individuals with intrinsic lung disease can be identified as having pulmonary hypertension if the main pulmonary artery is greater than 29 mm.
CT is a useful noninvasive procedure for confirming the presence of pulmonary hypertension (see Image 4).
The upper limit of normal for the diameter of the pulmonary artery is 28.6 mm. A value greater than 28.6 mm suggests increased pressures in the pulmonary system.
Degree of Confidence
CTPA is the best method for demonstrating emboli. HRCT is useful for demonstrating lung disease, which may account for secondary pulmonary hypertension.
Magnetic Resonance Imaging
Findings
MRI with contrast enhancement allows one to distinguish between the pulmonary vasculature and mediastinal adenopathy.3,5
MRI has capabilities similar to those of echocardiography in the diagnosis and treatment of patients with pulmonary hypertension. MRI is useful for measuring the mass, volume, and overall function of the right ventricle. MRI is also useful for detecting shunt lesions contributing to pulmonary hypertension. Acute and chronic pulmonary thromboembolic disease can be confirmed by using this imaging modality.
Degree of Confidence
The disadvantages with MRI include limitations in individuals with cardiac pacemakers and defibrillators, its limited availability and cost, and difficulty in assessing estimate PA pressures with MRI.
Ultrasonography
Findings
In evaluating pulmonary hypertension, echocardiography can be used to identify secondary causes, such as congenital, valvular, and myocardial disease. In addition, one may estimate pulmonary artery systolic pressure with this method. Specifically, the World Health Organization (WHO) has defined pulmonary hypertension as a systolic pressure greater than 30 mm Hg; this corresponds to a tricuspid regurgitant velocity of 3.0 m/s on echocardiography.
The following findings for pulmonary hypertension are confirmed on echocardiography (see Image 5): (1) Right atrial and ventricular enlargement (If right ventricular end-diastolic pressures are greater than 20 mm hg, the risk of sudden death is relatively high.), (2) paradoxical movement of the interventricular septum, and tricuspid regurgitation.
Pulmonary hypertension. Selective right pulmonary arteriogram demonstrates large central pulmonary arteries and attenuation of the peripheral vessels, without any definite demonstrable thrombi.
Doppler echocardiography is the most reliable noninvasive method for estimating pulmonary artery pressure. Tricuspid regurgitation is often present in pulmonary hypertension. It is detected in more than 90% of patients with severe pulmonary hypertension, with a correlation of more than 95% when the pressure is measured by means of catheterization.
Nuclear Imaging
Findings
Radioisotope perfusion lung scanning is performed with intravenous injection of particles of albumin labeled with technetium-99m. As these particles perfuse the lung, the lungs are imaged by using a gamma camera to obtain anterior, posterior, lateral, and oblique views. One would expect a normal distribution of these particles, which produce 2 blackened lung-shaped shadows.
In PPH, the V/Q scan is usually normal.
Pulmonary hypertension. Selective left pulmonary arteriogram reveals large central pulmonary arteries and attenuation of the peripheral vessels, without thrombi.
In secondary pulmonary hypertension due to chronic thromboembolic disease, emboli are responsible for blocking the branches of the pulmonary artery. The lung tissue peripheral to the block is not perfused; this block results in a defect on the scan. When findings in the perfusion scan are abnormal, a ventilation scan is obtained next by using inhalational radioactive xenon-133. A number of lung diseases, including pneumonia and COPD, can cause alterations in the ventilation component, whereas uncomplicated PE does not. Thus, a patient with a high likelihood of PE has an abnormal perfusion scan with a normal ventilation component (see Image 6).
Angiography
Findings
Right heart catheterization may be required (see Image 7). Pulmonary angiography is the most accurate modality for evaluating the anatomy and pathophysiology of pulmonary hypertension. Berberich and Hirsch obtained the first pulmonary angiogram in 1923, and Robb and Steinberg later optimized the technique in 1931. This examination is the criterion standard for the diagnosis of pulmonary hypertension.
Pulmonary hypertension. Image shows an example of the successful resolution of secondary pulmonary arterial hypertension in a patient who underwent pulmonary arterial thromboendarterectomy with the removal of thrombi.
Pulmonary angiography should be performed when the results of V/Q scanning cannot exclude chronic thromboembolic disease as an etiology for the elevated pulmonary pressures. The angiogram reveals large central pulmonary arteries with marked peripheral tapering.
The disadvantage of pulmonary angiography is that it is an invasive procedure as one cannulates the right side of the heart and the pulmonary artery. Complications include (1) transient rhythm disturbances that respond to the removal of the catheter, (2) cardiac perforation leading to pericardial tamponade, and (3) nephrotoxicity. In patients with an elevated creatinine level (1.5 X normal), the use of high-osmolar contrast material poses a risk of nephrotoxicity. This problem is less commonly seen with the selective use of small amounts of low-osmolar nonionic contrast material. The frequency of complications with pulmonary angiography is limited to <5% of cases examined.
More on Pulmonary Hypertension |
| Overview: Pulmonary Hypertension |
 Imaging: Pulmonary Hypertension |
| Follow-up: Pulmonary Hypertension |
| Multimedia: Pulmonary Hypertension |
| References |
| Further Reading |
| « Previous Page | Next Page » |
References
[Best Evidence] Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. Jan 15 2009;179(2):151-7. [Medline].
Revel MP, Faivre JB, Remy-Jardin M, Delannoy-Deken V, Duhamel A, Remy J. Pulmonary hypertension: ECG-gated 64-section CT angiographic evaluation of new functional parameters as diagnostic criteria. Radiology. Feb 2009;250(2):558-66. [Medline].
Koito H. [The findings of computed tomography (CT) and magnetic resonance imaging (MRI) in pulmonary arterial hypertension]. Nippon Rinsho. Nov 2008;66(11):2114-23. [Medline].
Devaraj A, Wells AU, Meister MG, Corte TJ, Hansell DM. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology. Dec 2008;249(3):1042-9. [Medline].
Kovacs G, Reiter G, Reiter U, Rienmüller R, Peacock A, Olschewski H. The emerging role of magnetic resonance imaging in the diagnosis and management of pulmonary hypertension. Respiration. 2008;76(4):458-70. [Medline].
[Best Evidence] Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. Feb 2009;30(4):394-403. [Medline].
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. Feb 1 1996;334(5):296-302. [Medline].
Abman SH. Neonatal pulmonary hypertension: A physiologic approach to treatment. Pediatr Pulmonol. Feb 2004;37 Suppl 26:127-8.
Aschner JL. New therapies for pulmonary hypertension in neonates and children. Pediatr Pulmonol. Feb 2004;37 Suppl 26:132-5.
Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. Jul 9 1992;327(2):70-5. [Medline].
Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug- induced pulmonary hypertension. Chest. Sep 1997;112(3):714-21. [Medline].
Fraser RG, Pare JA, Pare PD. Pulmonary hypertension and edema. In: Diagnosis of Diseases of the Chest. Vol 3. 4th ed. Philadelphia: WB Saunders;. 1999.
Gaine SP, Rubin LJ. Primary pulmonary hypertension [published erratum appears in Lancet 1999 Jan 2;353(9146):74]. Lancet. Aug 29 1998;352(9129):719-25. [Medline].
Gonçalves RC, Buschpigell CA, Lopes AA. Circulating blood volumes in pulmonary hypertension associated with erythrocytosis--the effects of therapeutic hemodilution. Cardiol Young. Dec 2003;13(6):544-50. [Medline].
Grossman W, Braunwald E. Pulmonary hypertension. In: Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders;. 1997.
Lilienfeld DE, Rubin LJ. Mortality from primary pulmonary hypertension in the United States, 1979-1996. Chest. Mar 2000;117(3):796-800. [Medline].
Miller SW, Waltman AC. The pulmonary circulation. In: Radiology: Diagnosis, Imaging, Intervention. Philadelphia: Lippincott;. 2001.
Morgan JM, Griffiths M, du Bois RM, Evans TW. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest. Mar 1991;99(3):551-6. [Medline].
Pistolesi M, Milne ENC. Radiology of cardiopulmonary hemodynamic disturbances. In: Radiology: Diagnosis, Imaging, and Intervention. Philadelphia: Lippincott;. 2001.
Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. Aug 1987;107(2):216-23. [Medline].
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. Jul 9 1992;327(2):76-81. [Medline].
Rich S, Levitsky S, Brundage BH. Pulmonary hypertension from chronic pulmonary thromboembolism. Ann Intern Med. Mar 1988;108(3):425-34. [Medline].
Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. Apr 13 1999;99(14):1858-65. [Medline].
Rubin LJ. Primary pulmonary hypertension. Chest. Jul 1993;104(1):236-50. [Medline].
Rubin LJ. Primary pulmonary hypertension. N Engl J Med. Jan 9 1997;336(2):111-7. [Medline].
Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. Jun 1998;31(7):1650-7. [Medline].
Further Reading
Clinical guidelines
Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).
American College of Chest Physicians - Medical Specialty Society. 2001 Jan (revised 2008 Jun). 92 pages. NGC:006666
(1) Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. (2) 2007 addendum.
American College of Chest Physicians - Medical Specialty Society. 2004 Jul (addendum released 2007 Jun). Original guideline: 28 pages; addendum: 12 pages. NGC:005762
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.
European Society of Cardiology - Medical Specialty Society. 2004. 36 pages. NGC:004058
Clinical trials
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
Latent Pulmonary Hypertension (PH) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH )After Endarterectomy and Influence of Exercise and Respiratory Therapy
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease
Related eMedicine topics
Pulmonary Hypertension, Secondary
Pulmonary Hypertension, Primary
Pulmonary Hypertension, Idiopathic
Pulmonary Hypertension, Eisenmenger Syndrome
Pulmonary Hypertension, High Altitude
Keywords
pulmonary hypertension, pulmonary heart disease, vascular disease, hypertension, persistent fetal circulation syndrome, cardiovascular disease, primary pulmonary hypertension, PPH, secondary pulmonary arterial hypertension, SPAH
